Dosimetric characterization of radioactive sources employed in prostate cancer therapy.
OBJECTIVE
Three types of radiation sources are employed currently in the radiation treatment of prostate cancer, namely, external, implant, and high-dose-rate (HDR) sources using an afterloader method. The present article provides a detailed dosimetric characterization of several commercially available implant sources and an HDR source employing the same stochastic code and dataset.


METHODS
The radioactive implants considered are (125)I seeds: models 6701, 6702 and 6711, (103)Pd seed: model 200, and a high-dose-rate (192)Ir source: microSelectron-HDR model V7.0x. Detailed modeling of the sources and their associated X-rays and gamma rays has been carried out using the stochastic code MCNP4C. A sensitivity study has been conducted to quantify effects of varying the composition and density of the tissue equivalent material, and a dosimetric comparison is made for different media (tissue equivalent, solid-water, water, and air). Furthermore, a set of measurements using thermoluminescent dosimeters has been done to provide experimental validation of some of the calculational results obtained.


RESULTS
Effectively, high-precision dosimetric values (Monte-Carlo statistical 1-sigma error <1%) are provided in tabulated form over a wide range to enable therapy planning as well as to check numerical values calculated by other methods. A subset of calculated dosimetric values has been experimentally validated by using thermoluminescent dosimeters.


CONCLUSIONS
A detailed comparison of results obtained for the radial dose distribution function, anisotropy factor, and dose rate constant as defined in the TG-43 protocol has indicated reasonable agreement with the values reported in the literature.
Zilio
Valery Olivier
VO
Polytechnic Federal School of Lausanne, Institute of the Energy of Physics & Particles, Reactor Physics and Systems Laboratory, CH-1015 Lausanne, Switzerland.
Joneja
Om Parkash
OP
Popowski
Youri
Y
Chawla
Rakesh
R
D001918:Brachytherapy / Q000295:instrumentation*; D003198:Computer Simulation; D006801:Humans; D007457:Iodine Radioisotopes / Q000592:standards / Q000627:therapeutic use; D007496:Iridium Radioisotopes / Q000592:standards / Q000627:therapeutic use; D008297:Male; D010165:Palladium / Q000592:standards / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000592:standards* / Q000627:therapeutic use; D011874:Radiometry; D011881:Radiotherapy, Computer-Assisted
D007457:Iodine Radioisotopes; D007496:Iridium Radioisotopes; D011868:Radioisotopes; D010165:Palladium